** Shares of AnaptysBio ANAB.O fall as much as 38.5% to an over one-year low of $14.20

** Stock set for worst day since Nov 2019, if losses hold

** Co says it will discontinue development of its eczema drug ANB032 after it failed to meet the goals of a mid-stage trial

** Drug did not meet the main goal of a proportion of patients achieving an at least 75% improvement of symptoms on an eczema severity index

** ANAB will focus on the rest of its autoimmune portfolio, which includes drugs for rheumatoid arthritis and a type of inflammatory bowel disease - CEO

** Up to last close, stock down 30.6% YTD

(Reporting by Puyaan Singh)

((Puyaan.Singh@thomsonreuters.com;))